Pokrovsky S N, Sussekov A V, Adamova I Y, Afanasieva O I, Benevolenskaya G F, Konovalov G A, Kukharchuk V V
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.
Artif Organs. 1995 Jun;19(6):500-5. doi: 10.1111/j.1525-1594.1995.tb02369.x.
Three types of sorbents were developed for the specific removal of atherogenic apoB-containing low-density lipoprotein (LDL) and lipoprotein LDL (a) (Lp[a]) from human plasma. Two sorbents contained monospecific sheep polyclonal or mouse monoclonal antibodies against human apoprotein B-100. The third one was intended for specific removal of Lp(a) and contains sheep antibodies against human Lp(a). Thirty patients were treated for up to 9 years by LDL apheresis with anti-LDL immunosorbents. A pilot study of Lp(a) apheresis with 3 patients was conducted during 3 years. The results showed that extracorporeal immunosorption is safe and effective for lowering LDL and Lp(a). These procedures may be used both for metabolic investigations and for studies on possible regression of atherosclerosis.
为了从人血浆中特异性去除致动脉粥样硬化的含载脂蛋白B的低密度脂蛋白（LDL）和脂蛋白LDL（a）（Lp[a]），研发了三种吸附剂。两种吸附剂含有针对人载脂蛋白B-100的单特异性绵羊多克隆抗体或小鼠单克隆抗体。第三种吸附剂旨在特异性去除Lp(a)，含有针对人Lp(a)的绵羊抗体。30名患者接受了使用抗LDL免疫吸附剂的LDL单采术治疗，长达9年。对3名患者进行了为期3年的Lp(a)单采术初步研究。结果表明，体外免疫吸附对于降低LDL和Lp(a)是安全有效的。这些程序可用于代谢研究以及动脉粥样硬化可能消退的研究。
